Nephrotic Syndrome Associated with Thymoma  by Hsiao, Sheng-Yen et al.
 Case Report  
Nephrotic Syndrome Associated with Thymoma 
Sheng-Yen Hsiao1,2, Kwang-Yu Chang1,2, Jang-Yang Chang1,2, Wu-Chou Su2* 
1National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan 
2Division of Oncology and Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, 
College of Medicine, National Cheng Kung University, Tainan, Taiwan  
Abstract. 
Thymoma is associated with a wide variety of paraneoplastic syndromes such as myasthe-
nia gravis, pure red cell aplasia, and hypogammaglobulinemia. Paraneoplastic glomerulone-
phritis is a rare clinical presentation of malignancy. This condition often goes undetected as it 
has no specific clinical symptoms and signs. Approximately 2% of thymoma patients have 
been reported to have paraneoplastic glomerulonephritis, and the nephrotic syndrome has been 
shown to be a clinical manifestation of the disorder. We report two cases diagnosed to have 
thymoma and nephrotic syndrome. Renal biopsy showed that one case had focal segmental 
glomerulosclerosis, whereas the other had minimal change disease. In case 1, the nephrotic 
syndrome was diagnosed before thymoma was detected, while in case 2, the symptomatic ne-
phrotic syndrome occurred after thymoma treatment. Because parathymic nephropathy often 
remains undiagnosed and interferes with treatment, the possibility of the nephrotic syndrome 
should always be considered throughout the course of thymoma management, particularly in 
patients who also present with anasarca or hypoalbuminemia. A multidisciplinary approach is 
needed. Besides, it is to be noted that the nephrotic syndrome may be the initial presentation of 
thymoma. 
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中文摘要 
  胸腺瘤在臨床表現上會伴隨各種不同附腫瘤性症候群，如重症肌無力症，純紅血球
再生不良或低免疫球蛋白血症。附腫瘤性腎病在惡性腫瘤的臨床表現上是很少見的。因
為缺乏特定的臨床表徵，我們容易忽略這種狀況。根據從前的文獻，大約有百分之二胸
腺瘤病人在臨床上有附腫瘤性腎病，腎病症候群是其中一種表現。我們報導兩個在台灣
胸腺瘤的病人，臨床上也有腎病症候群的診斷。腎臟切片診斷其中一個是局部性腎絲球
硬化症，另一個是微小病變性腎病。第一個報告案例中，腎病症候群出現在胸腺瘤診斷
之前，而另一個病人的腎病症候群出現在胸腺瘤治療之後。因為容易忽略的臨床表現以
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 及對治療的影響，治療胸腺瘤病人時，如果臨床上出現全身水腫或低蛋白血症，都應該
要考慮腎病症候群的可能性，並且治療上也需要多團隊的協助。另外值得注意的是，腎
病症候群可能是胸腺瘤病人最初的臨床表現。 
 
關鍵字: 胸腺瘤、腎病症候群、附腫瘤性腎病 
INTRODUCTION 
Thymoma is a neoplastic disease that originates in 
the thymus, an important organ in the development of 
the lymphoid system. It is distinct from other onco-
logical diseases, particularly its invasive subtype, 
thymic carcinoma because of its slow growth rate and 
the associated paraneoplastic syndrome. Associations 
between thymoma and syndromes such as myasthenia 
gravis, pure red cell aplasia and hypogammaglobu-
linemia have been frequently noted in the literature. 
Therefore, differential diagnosis of thymoma is usual-
ly easy and clear-cut because such a syndrome is 
rarely found in other malignancies. On the other hand, 
the identification of rarer and less well-known para-
neoplastic syndromes is often challenging. Further-
more, the infrequent symptoms are often nonspecific 
clinically and in images. One disorder is the nephrotic 
syndrome, which is a rare but clinically distinct para-
neoplastic syndrome associated with thymoma. In this 
paper, we report two cases of thymoma accompanied 
by the nephrotic syndrome. 
 
CASE REPORTS 
 
Case 1 
A 62-year-old female visited our nephrology out-
patient department in December 2009, initially for 
persistent foamy urine and swelling of the legs for 
more than 3 months. According to her medical history, 
she was a chronic hepatitis B and hepatitis C virus 
carrier, but otherwise in good physical health. Physical 
examination showed pitting edema restricted to both 
lower extremities. Laboratory examination of serum 
samples showed hypoalbuminemia of 2.5 g/dl (normal 
range: 3.5-5 g/dl) and hypercholesterolemia of 426 
mg/dl (normal range: 35-135 mg/dl). Liver and renal 
function tests were within the normal limits. Routine 
urine analysis revealed hematuria and proteinuria 
(RBC: 32/HPF, WBC: 10/HPF, protein: 3+ on dip-
stick). Glucose and nitrite were not detected in the 
urine. Further examination of a 24-h urine test showed 
severe proteinuria of 13.8 g/day. Renal ultrasound 
showed normal echogenicity and size in both kidneys. 
Due to the suspected diagnosis of nephrotic syndrome, 
renal biopsy was performed. The results of histology 
by optical microscopic examination revealed that 
some glomeruli were involved in sclerosis and some 
glomeruli had mesangial expansion (Figure 1A). In 
addition, glomerular basement membrane retraction 
and segmental wrinkling as well as foot process ef-
facement were found using electron microscopy (Fig-
ure 1B). Together, these results suggested a character-
istic finding of focal segmental glomerulosclerosis 
(FSGS). Possible immune defects associated with the 
nephrotic syndrome were investigated using serum 
tests of antinuclear antibodies, C3/C4, anti-neutrophil 
cytoplasmic antibodies, screening anti-HIV antibodies, 
cryoprotein, and immunoglobulin levels. However, 
results were all negative. No other data were found to 
explain the above-mentioned findings, and the direct 
cause of the syndrome was not identified at that time. 
Observation only was carried out until November 
2010, when rapid deterioration of the renal function 
occurred. Serum creatinine levels increased from 0.89  
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Figure 1. Histological findings of renal biopsy in case 1. Figure 1A: optical microscopy revealed sclerosis of 
glomeruli (arrow) and mesangial expansion (arrowhead). Figure 1B: electron microscopy showed ef-
facement of food process (arrow). Original magnification, X400 in figure 1A and X10,000 in figure 1B 
 
 
mg/dl to 4.6 mg/dl. The patient received methylpred-
nisolone therapy for 8 months, with progressive im-
provement in both the renal function and rate of urine 
protein loss. 
At a regular follow-up session at our hospital in 
August 2011, the patient complained of having non-
specific airway symptoms for several days. A chest 
X-ray showed widening of the mediastinum, which 
was distinctly different from previous imaging find-
ings. However, there were no significant lung paren-
chymal abnormalities. Chest computed tomography 
undertaken for surveillance purposes showed an ante-
rior mediastinal mass, which was suspected to be 
thymoma (Figure 2). No other symptoms relating to 
the paraneoplastic syndrome of thymoma, such as pit-
ting edema, anasarca, or fluctuating muscle weakness 
and fatigability, were observed at the time. Laboratory 
tests showed no hypoalbuminemia or proteinuria. For 
the treatment of the localized disease, video-assisted 
thoracic thymectomy was performed for October 2011. 
A review of pathologic examination of the resected 
specimen showed major composition of epithelial cell 
tissue, consistent with type A thymoma (Figure 3A). 
Ever since the patient underwent thymectomy neither 
thymoma nor nephrotic syndrome has recurred (at the 
last outpatient surveillance appointment in June 2013, 
the serum albumin level was 4.2 g/dl and physical 
examination revealed no anasarca). 
 
Case 2 
A 47-year-old woman visited our department pre-
senting with intermittent chest dullness, pain, and 
progressive dyspnea for more than 3 months. Physical 
examination revealed reduced breathing sounds in the 
left lung. A chest X-ray showed multiple left lung 
nodules. Computed tomography further showed an 
anterior mediastinal mass and multiple tumors in the 
left pleural space and pericardium, and thymoma with 
metastases was suspected. Accordingly, surgical in-
tervention for the excision of the thymoma, left 
pneumonectomy, and partial pericardiectomy was 
performed in July 2003. A pathological examination 
revealed tumor cells bearing a resemblance to epithe-
lial cells of normal thymic cortex, and some small 
lymphocyte infiltration was noted in the tumor tissue. 
These features led to a diagnosis of invasive thymoma, 
type B2 (Figure 3B). The patient received concurrent 
chemoradiotherapy with cisplatin for adjuvant therapy  
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Figure 2. In case 1, chest computed tomography in 
August 2011 revealed anterior mediastinal 
mass (white arrow) 
 
 
and regular follow-up for 2 years.  
In November 2009, the patient returned to our 
hospital for dyspnea and general fatigue. New lesions 
were noted by computed tomography showing left 
pleural masses with pleural effusion. Biopsy of the 
mass confirmed recurrent thymoma. Because of the 
unresectable disease, chemotherapy with cyclophos-
phamide, doxorubicin, and cisplatin was administered 
for a total of six cycles. Although the pleural masses 
remained stable after treatment, significant body 
weight gain with bilateral lower legs pitting edema 
and anasarca were noted in September 2011. In addi-
tion, the patient complained of foamy urine at that 
time. There were no symptoms of heart failure, and 
the results of liver and renal function tests were within 
the normal range. A routine urinalysis showed pro-
teinuria (RBC: 1/HPF, WBC: 6/HPF, protein: 3+ on 
dipstick). A 24 h urine test showed 8.1 g/day of urine 
protein. Hypercholesterolemia of 737 mg/dl (normal 
range: 35 to 135 mg/dl) was also noted. These find-
ings led to the diagnosis of nephrotic syndrome, and 
blood samples were taken and the medical history re-
viewed. The results indicated that viral hepatitis, dia-
betes, or autoimmune disease were unlikely to have 
induced this condition in the patient. Renal biopsy was 
undertaken and optical microscopy of the kidney tis-
sue was negative (Figure 4A). Nevertheless, electron 
microscopy revealed complete effacement of the foot 
process of the visceral epithelial cells (Figure 4B). 
The findings indicated a minimal change disease. For 
treatment, pulse methylprednisolone was administered 
immediately, followed by prednisolone and cyclo-
sporine. An excellent response was observed, with an 
estimated daily urine protein loss (by the spot urine 
sample) of only 190 mg/day 2 months after the inter-
vention. The patient died in January 2012 because of 
pneumonia and respiratory failure. The daily urine 
protein loss at that time remained relatively well con-
trolled, and was 490 mg/day. 
 
DISCUSSION 
The nephrotic syndrome is associated with a wide 
variety of primary and secondary diseases [1]. Renal 
biopsy is the standard procedure for diagnosis of the 
cause of changes in renal function. In case 1, the re-
sults of renal biopsy revealed FSGS. Though the pa-
tient was a carrier of viral hepatitis, the FSGS was 
deemed unlikely to be related to the infectious disease. 
Membrane nephropathy is the most frequent change 
related to hepatitis B viral infection [2]. In contrast, 
type I membranoproliferative glomerulonephritis as-
sociated with type II cryoglobulinemia is known to be 
more strongly associated with hepatitis C viral infec-
tion [3]. Therefore, the thymoma found later as the 
underlying cause, provides a reasonable explanation 
for the previous findings. In case 2, pathological find-
ings showed minimal change disease. Besides thy-
moma, no other etiology was identified that could 
cause the nephrotic syndrome. Although cytotoxic 
agents such as cisplatin are known to induce ne-
phrotoxicity, it is known that this typically causes tub-
ular dysfunction.  
 The causal relationship between thymoma and 
several types of the paraneoplastic syndrome, includ-
ing myasthenia gravis, pure red cell aplasia, and hy-
pogammaglobulinemia, is well established. For para-
neoplastic glomerulonephritis in thymoma, the associ- 
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Figure 3. Histological findings from specimens of thymoma in two cases. A: thymoma, type A in case 1. B: thy-
moma, type B2 in case 2. Original magnification, X400 
 
 
ation remains ambiguous because of the fact that only 
approximately 2% of patients are affected [4]. In thy-
moma, the most common renal change is minimal 
change disease. Other disorders associated with thy-
moma include membrane nephropathy, FSGS, and 
rapidly progressing glomerulonephritis [4]. Because 
the syndrome is rare and usually presents along with 
nonspecific symptoms and signs, the association with 
neoplastic diseases is often underestimated. The first 
case series of paraneoplastic nephropathy was pub-
lished approximately 40 years ago by Lee et al. [5]. 
Since then, Hodgkin lymphoma-associated minimal 
change disease and solid tumor-associated membrane 
nephropathy have been recognized as classic parane-
oplastic nephropathy [6,7]. Posner et al. were the first 
to suggest an association between glomerulonephritis 
and thymoma in 1980 [8]. The association between 
thymoma and the renal disorder is still not often re-
ported, due to the rarity of the condition. The largest 
case series was reported by Karras et al., which in-
cluded 21 cases [9]. It has been reported that different 
histological types of thymoma may result in distinct 
pathologic changes and different times of onset of 
glomerulonephritis. Epithelium-predominant thymoma 
was reported more often with membrane nephropa-
thy, and the disorder was diagnosed more often in 
tandem with the neoplasm. In contrast, lymphocyte- 
predominant thymoma tends to appear in minimal 
change disease. The onset of symptoms and signs was 
frequent after tumor treatment [9].  
Types of renal disorder differed between our cases. 
The relationship between the findings of renal biopsy 
and thymoma were consistent with previous reports, 
particularly in case 2. This patient had type B2 thy-
moma with predominant lymphocyte infiltration into 
the tumor tissue and she also contracted nephropathy 
compatible with minimal change disease. The onset 
time of renal disorder also differed between these two 
cases. In case 1, nephropathy was detected before 
thymoma was diagnosed. Although we did not find 
thymoma at the time of onset of the nephrotic syn-
drome, simultaneous existence of immune dysregula-
tion with undetected thymoma may have been the 
cause. In case 2, nephropathy presented with anasarca 
and proteinuria after treatment for recurrent thymoma. 
There is no clear understanding as to why nephrotic 
syndrome does not occur at the same time as the ini-
tial diagnosis. In a reported case series, ten of 21 pa-
tients who presented with nephrotic syndrome after 
diagnosis of thymoma showed a median delay of 2  
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Figure 4. Histological finding of renal biopsy from case 2. A: optical microscopy revealed nearly normal finding 
of renal histology. B: electron microscopy showed complete effacement at foot process of visceral epi-
thelial cells (arrow). Original magnification, X400 in figure 1A and X10,000 in figure 1B 
 
 
years between thymoma diagnosis and onset of 
nephropathy. In the discussion, the authors proposed 
that immune dysregulation may play an important role 
in pathogenesis [9]. Therefore, the nephrotic syn-
drome may not appear at the same time as thymoma. 
The link between thymoma and nephropathy is not 
fully understood. As a general rule, diagnosis of para-
neoplastic syndrome is based on conditions including 
occurrence with concurrent malignancy, remission 
after malignancy treatment, and the flare up with 
malignancy recurrence [4]. However, parathymic 
nephropathy is not fully consistent with these three 
rules. This is because the thymus plays an important 
role in the maturation of T lymphocytes through the 
mechanism of positive and negative selection. There-
fore, an imbalance between autoreactive lymphocytes 
and immunoregulatory mechanisms can take place 
before or even after thymoma treatment [10,11]. This 
may be attributable to the wide variety of the thy-
moma-associated paraneoplastic syndrome. In the case 
of nephrotic syndrome, the immunological disorder 
was supported by animal model using the Buffa-
lo/Mna rats, which are known to carry thymoma. The 
nephrotic syndrome with proteinuria, hypoalbu-
minemia, and hyperlipidemia was observed when the 
mice were eight weeks of age [12,13]. Notably, thy-
mectomy in adult Buffalo/Mna rats did not alter the 
course of proteinuria, suggesting that thymoma itself 
has no direct interaction with nephropathy [14]. Le 
Berre et al. have demonstrated that renal macrophage 
activation and Th2 polarization precede the nephrotic 
syndrome, which implies that immunological disorder 
may play an important role in the pathogenesis of 
thymoma-associated nephropathy [13]. 
In the largest case series published so far [9], most 
patients presenting with nephropathy were treated ini-
tially with steroids. One patient with frequent relapses 
and two with partial response were treated with other 
immunosuppressive drugs, such as cyclosporine. 
Nevertheless, the record showed that some patients 
who were in remission for nephropathy also had direct 
treatment for thymoma (surgery, radiotherapy, or 
chemotherapy). Therefore, the effect of direct thy-
moma treatment upon nephropathy remains unclear. 
In clinical practice, direct treatment of the underlying 
tumor disease is sufficient to alleviate some of para-
thymic disorders such as nephropathy and myasthenia 
gravis. In contrast, additional therapy with immuno-
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 suppressive drugs such as steroid or cyclosporine 
should also be considered in the treatment of thy-
moma associated nephropathy [9,15,16].  
Although only 2% of patients with thymoma have 
nephrotic syndrome in clinical practice, identification 
of the disorder is of critical importance. These patients 
usually have poor renal function. The administration 
of chemotherapy, such as cisplatin, may further impair 
renal function and is of concern. Patients with ne-
phrotic syndrome may be at an increased risk of infec-
tion due to loss of immunoglobulin, and may also be 
at an increased risk of neutropenic sepsis [17]. Several 
case reports have described thymoma presenting ini-
tially with nephrotic syndrome, and chest images 
should be considered for these patients to rule out 
possible underlying tumor disease [9,18]. 
In conclusion, we have reported two cases of ne-
phrotic syndrome associated with thymoma. Histo-
logical findings of renal biopsy and clinical presenta-
tions differed between these two cases. The observa-
tion on the cases and a literature review reinforce the 
importance of paraneoplastic glomerulonephritis in 
thymoma. When patients with thymoma have deterio-
rated renal function or anasarca, nephrotic syndrome 
is a possible diagnosis. Further treatment modification 
such as dose adjustment or prevention and control of 
infectious diseases is needed for this condition. Fur-
thermore, nephrotic syndrome may be an initial 
presentation of thymoma. Therefore, in such cases 
chest image surveillance should be considered, partic-
ularly for patients with undetected or ambiguous eti-
ology of the nephrotic syndrome. 
 
REFERENCES 
1. Orth SR, Ritz E. The Nephrotic Syndrome. N 
Engl J Med 338: 1202-1211, 1998. 
2. Khedmat H, Taheri S. Hepatitis B virus-associated 
nephropathy: an International Data Analysis. Iran 
J Kidney Dis 4: 101-5, 2010. 
3. Morales JM, Kamar N, Rostaing L. Hepatitis C 
and renal disease: epidemiology, diagnosis, path-
ogenesis and therapy. Contrib Nephrol 176: 
10-23, 2012. 
4. Lien YH, Lai LW. Pathogenesis, diagnosis and 
management of paraneoplastic glomerulonephritis. 
Nat Rev Nephrol 7: 85-95, 2011. 
5. Lee JC, Yamauchi H, Hopper J Jr. The associa-
tion of cancer and the nephrotic syndrome. Ann 
Intern Med 64: 41-51, 1966. 
6. Audard V, Larousserie F, Grimbert P, et al. Min-
imal change nephrotic syndrome and classical 
Hodgkin's lymphoma: report of 21 cases and re-
view of the literature. Kidney Int 69: 2251-60, 
2006. 
7. Bacchetta J, Juillard L, Cochat P, et al. Parane-
oplastic glomerular diseases and malignancies. 
Crit Rev Oncol Hematol 70: 39-58, 2009. 
8. Posner MR, Prout MN, Berk S. Thymoma and the 
nephrotic syndrome: a report of a case. Cancer 45: 
387-91, 1980. 
9. Karras A, de Montpreville V, Fakhouri F, et al. 
Renal and thymic pathology in thymoma-    
associated nephropathy: report of 21 cases and 
review of the literature. Nephrol Dial Transplant 
20: 1075-82, 2005. 
10. Hoffacker V, Schultz A, Tiesinga JJ, et al. Thy-
momas alter the T-cell subset composition in the 
blood: a potential mechanism for thymoma-   
associated autoimmune disease. Blood 96: 3872-9, 
2000. 
11. Gerli R, Paganelli R, Cossarizza A, et al. Long- 
term immunologic effects of thymectomy in pa-
tients with myasthenia gravis. J Allergy Clin 
Immunol 103: 865-72 1999. 
12. Kato F, Watanabe M. Biochemical study on 
spontaneous thymoma rats with motor dysfunc-
tion. J Pharmacobiodyn 6: 275-9 1983. 
13. Le Berre L, Herve C, Buzelin F, et al. Renal 
macrophage activation and Th2 polarization pre-
cedes the development of nephrotic syndrome in 
Buffalo/Mna rats. Kidney Int 68: 2079-90, 2005. 
14. Nakamura T, Matsuyama M, Kojima A, et al. The 
S. Y. Hsiao et al./JCRP 1(2014) 233-240 239
 effect of thymectomy on the development of 
nephropathy in spontaneous thymoma rats of the 
BUF/Mna strain. Clin Exp Immunol 71: 350-2, 
1988. 
15. Fukuda A, Sato Y, Iwatsubo S, et al. Minimal 
change nephrotic syndrome complicated with re-
currence of malignant thymoma: an interesting 
case with remission due to steroid therapy of both 
nephrotic syndrome and thymoma. Nihon Jinzo 
Gakkai Shi 51: 130-7, 2009. 
16. Lee HC, Cheng YF, Chuang FR, et al. Minimal 
change nephrotic syndrome associated with ma-
lignant thymoma: case report and literature re-
view. Chang Gung Med J 24: 576-81, 2001. 
17. Teoh DC, El-Modir A. Managing a locally ad-
vanced malignant thymoma complicated by ne-
phrotic syndrome: a case report. J Med Case Rep 
2: 89, 2008. 
18. Federico A, Merletti MG, Lisi E, et al. Nephrotic 
syndrome as first presentation of malignant thy-
moma: description of a clinical case. G Ital Ne-
frol 27: 674-9, 2010.  
240 S. Y. Hsiao et al./JCRP 1(2014) 233-240
